SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Alexandros Makriyannis, 2012 Division of Medicinal Chemistry Award Address. Trekking the Cannabinoid Road: A Personal Perspective, Journal of Medicinal Chemistry, 2014, 57, 10, 3891

    CrossRef

  2. 2
    Kun Li, Jakub Fichna, Rudolf Schicho, Dieter Saur, Mohammad Bashashati, Ken Mackie, Yongyu Li, Andreas Zimmer, Burkhard Göke, Keith A. Sharkey, Martin Storr, A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice, Neuropharmacology, 2013, 71, 255

    CrossRef

  3. 3
    Rudolf Schicho, Martin Storr, A potential role for GPR55 in gastrointestinal functions, Current Opinion in Pharmacology, 2012, 12, 6, 653

    CrossRef

  4. 4
    David R. Janero, Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists, Expert Opinion on Emerging Drugs, 2012, 17, 1, 17

    CrossRef

  5. 5
    G. R. MARTIN, A. L. ALVAREZ, M. BASHASHATI, C. M. KEENAN, F. R. JIRIK, K. A. SHARKEY, Endogenous cellular prion protein regulates contractility of the mouse ileum, Neurogastroenterology & Motility, 2012, 24, 9
  6. 6
    Mallappa Anitha, Matam Vijay–Kumar, Shanthi V. Sitaraman, Andrew T. Gewirtz, Shanthi Srinivasan, Gut Microbial Products Regulate Murine Gastrointestinal Motility via Toll-Like Receptor 4 Signaling, Gastroenterology, 2012, 143, 4, 1006

    CrossRef

  7. 7
    Angelo A Izzo, Raffaele Capasso, Gabriella Aviello, Francesca Borrelli, Barbara Romano, Fabiana Piscitelli, Laura Gallo, Francesco Capasso, Pierangelo Orlando, Vincenzo Di Marzo, Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice, British Journal of Pharmacology, 2012, 166, 4
  8. 8
    Antonia Serrano, Francisco Javier Pavon, Juan Suarez, Miguel Romero-Cuevas, Elena Baixeras, Pilar Goya, Fernando Rodríguez Fonseca, Obesity and the Endocannabinoid System: Is There Still a Future for CB1 Antagonists in Obesity?, Current Obesity Reports, 2012, 1, 4, 216

    CrossRef

  9. 9
    B. S. Wong, M. Camilleri, D. Eckert, P. Carlson, M. Ryks, D. Burton, A. R. Zinsmeister, Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea, Neurogastroenterology & Motility, 2012, 24, 4
  10. 10
    Mireille Alhouayek, Giulio G. Muccioli, The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity, Trends in Molecular Medicine, 2012, 18, 10, 615

    CrossRef

  11. 11
    David R Janero, Loren Lindsley, Venkata Kiran Vemuri, Alexandros Makriyannis, Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk, Expert Opinion on Drug Discovery, 2011, 6, 10, 995

    CrossRef

  12. 12
    R. Abalo, P. A. Cabezos, G. Vera, V. López-miranda, E. Herradón, M. I. Martín-fontelles, Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent administration in the rat: role of CB1 receptors, Neurogastroenterology & Motility, 2011, 23, 5
  13. You have free access to this content13
    V. Di Marzo, F. Piscitelli, Gut feelings about the endocannabinoid system, Neurogastroenterology & Motility, 2011, 23, 5
  14. 14
    Vincenzo Di Marzo, Luciano De Petrocellis, Fifty years of ‘cannabinoid research’ and the need for a new nomenclature,